Related Experiment Videos
Fulminant Mycoplasma pneumoniae pneumonia
1Division of Pulmonary Sciences, University of Colorado Health Sciences Center, Denver 80262, USA.
Abstract:
The frequency of fulminant pneumonia due to Mycoplasma pneumoniae is relatively rare despite the high prevalence of Mycoplasma species infection in the general population. We recently encountered such a case and have reviewed the English-language literature on cases of M pneumoniae pneumonia that have resulted in respiratory failure or death. Due to host factors or on epidemiologic grounds, fulminant cases seem to be more common in young healthy adults, in males, and possibly in smokers among the 46 patients we found. An enhanced host cellular immune response may be responsible for the development of severe cases. A spectrum of small airways disease is characteristic, including cellular bronchiolitis and bronchiolitis obliterans with and without organizing pneumonia. Based largely on anecdotal experience, corticosteroid use may be salutary in patients with respiratory failure. For reasons that are not well known, the incidence of pulmonary thromboembolism is increased in fatal cases.
Insights
Fulminant pneumonia from Mycoplasma pneumoniae is rare but severe, often affecting young males. Enhanced immune responses may drive severe cases, with corticosteroids potentially aiding recovery.
Area of Science:
- Pulmonology
- Infectious Diseases
- Immunology
Background:
- Mycoplasma pneumoniae infections are common, but severe, fulminant pneumonia is rare.
- This study reviews literature on fatal or respiratory failure-inducing M. pneumoniae pneumonia cases.
Observation:
- Fulminant cases disproportionately affect young, healthy adult males, and possibly smokers.
- Histopathology reveals small airways disease, including cellular bronchiolitis and bronchiolitis obliterans.
Findings:
- An enhanced host cellular immune response is hypothesized to cause severe disease.
- Pulmonary thromboembolism is notably increased in fatal cases.
Implications:
- Corticosteroids may benefit patients experiencing respiratory failure.
- Understanding host factors is crucial for managing severe Mycoplasma pneumoniae pneumonia.